Month: May 2024

Advancing TPST-1120 into a pivotal Phase 3 trial in first-line HCC and TPST-1495 into a Phase 2 in FAP Reported new preclinical data for TPST-1120 in kidney cancer at the AACR Annual Meeting Published positive data from the Phase 1 Trial of TPST-1120 in patients with advanced solid tumors in the Journal of Cancer Research Communications Presented new data at the SITC 2024 Spring Scientific Meeting elucidating the mechanism of TPST-1120 and supporting its potential in multiple cancersBRISBANE, Calif., May 09, 2024 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the quarter ended March 31, 2024, and provided a corporate update. “The positive data...

WESTLAKE VILLAGE, Calif., May 09, 2024 (GLOBE NEWSWIRE) — Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2024 and provided general business updates.   “Our pivotal Phase 3 registration trial of Olvi-Vec in platinum resistant/refractory ovarian cancer continues to enroll patients,” said Thomas Zindrick, President, Chairman and CEO of Genelux. “Looking ahead, we are excited about advancing Olvi-Vec into additional cancer indications through intravenous administration, a physician-preferred route of delivery, and seeking to further validate our hypothesis that Olvi-Vec may reverse resistance to platinum in multiple tumor types.” The Company expects to initiate our Phase 2 trial in recurrent non-small cell lung cancer in the second quarter...

Quarterly revenue of $821 million; GAAP EPS of $0.45 and adjusted EPS of $0.97 DALLAS, May 09, 2024 (GLOBE NEWSWIRE) — AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, today announced its first quarter 2024 financial results. Financial highlights are as follows: Dollars in millions, except per share amounts.  Q1 2024 % Change Q1 2023Revenue $820.9 (27%)  Gross profit $257.5 (30%)  Net income $17.3 (79%)  GAAP diluted EPS $0.45 (78%)  Adjusted diluted EPS* $0.97 (61%)  Adjusted EBITDA* $97.7 (46%)  * See “Non-GAAP Measures” below for a discussion of our use of non-GAAP items and the table entitled “Non-GAAP Reconciliation Tables” for a reconciliation of non-GAAP items. Business HighlightsFirst quarter revenue...

Dallas, Texas, May 09, 2024 (GLOBE NEWSWIRE) — Valhi, Inc. (NYSE: VHI) reported net income attributable to Valhi stockholders of $7.8 million, or $.27 per share, in the first quarter of 2024 compared to a net loss attributable to Valhi stockholders of $4.9 million, or $.17 per share, in the first quarter of 2023. Net income attributable to Valhi stockholders increased in the first quarter of 2024 as compared to the first quarter of 2023 primarily due to higher operating income from our Chemicals Segment partially offset by lower operating income from our Component Products Segment and our Real Estate Management and Development Segment. The Chemicals Segment’s net sales of $478.8 million in the first quarter of 2024 were $52.5 million, or 12%, higher than in the first quarter of 2023. The Chemicals Segment’s net sales increased...

Product Sales up a robust 14% over prior year, and a significant 22% sequentially We believe the STAR-T data presented at AATS support a favorable benefit-to-risk profile of DrugSorb-ATR in coronary artery bypass graft (CABG) patients On track for U.S. Food and Drug Administration (FDA) De Novo and Health Canada submissions for DrugSorb®-ATR in Q3 2024PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE) — CytoSorbents Corporation (NASDAQ: CTSO), a pioneer in critical care and cardiac surgery blood purification technologies, today reported unaudited financial and operating results for the quarter ended March 31, 2024. The Company reported a robust 14% increase in product sales year over year and a sequential quarterly increase of 22%. Dr. Phillip Chan, Chief Executive Officer of CytoSorbents stated, “We are pleased to announce a...

ROCHESTER, N.Y., May 09, 2024 (GLOBE NEWSWIRE) — Eastman Kodak Company (NYSE: KODK) today reported financial results for the first quarter 2024. First-quarter 2024 highlights include:Consolidated revenues of $249 million, compared with $278 million for Q1 2023, a decrease of $29 million or 10 percent Gross profit of $49 million, compared with $50 million for Q1 2023, a decrease of $1 million or 2 percent Gross profit percentage of 20 percent, compared with 18 percent for Q1 2023, an increase of 2 percentage points GAAP net income of $32 million, compared with net income of $33 million for Q1 2023, a decrease of $1 million or 3 percent Operational EBITDA of $4 million, compared with $9 million for Q1 2023, a decrease of $5 million or 56 percent A quarter-end cash balance of $262 million, compared with $255 million on December...

Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist; reiterating top-line data anticipated by year-end 2024 Enrollment ongoing for global Phase 2b trial to treat rheumatoid arthritis (RA) and global Phase 2 trial to treat ulcerative colitis (UC) with rosnilimab, our PD-1 agonist; reiterating top-line data anticipated by mid 2025 and H1 2026, respectively IND submissions for ANB033 (anti-CD122 antagonist) and ANB101 (BDCA2 modulator) anticipated Q2 2024 and H2 2024, respectively Announced positive top-line GEMINI-2 Phase 3 trial results of imsidolimab, our IL-36R mAb, in generalized pustular psoriasis Announced a $50 million capped non-recourse royalty monetization from amended agreement with Sagard in exchange for additional Jemperli royaltiesSAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE)...

– Q2 Sales increase 9% to $249 Million – Q2 GAAP EPS increases 30% to $0.90 – Q2 Adjusted EPS increases 24% to $0.94 – St. Louis, May 09, 2024 (GLOBE NEWSWIRE) — ESCO Technologies Inc. (NYSE: ESE) (ESCO, or the Company) today reported its operating results for the second quarter ended March 31, 2024 (Q2 2024). Operating HighlightsQ2 2024 Sales increased $20.0 million (9 percent) to $249.1 million compared to $229.1 million in Q2 2023. Q2 organic sales increased $17.8 million (8 percent) and the MPE acquisition contributed $2.2 million (1 percent) of revenue in the quarter.    Q2 2024 GAAP EPS increased 30 percent to $0.90 per share compared to $0.69 per share in Q2 2023. Q2 2024 Adjusted EPS increased 24 percent to $0.94 per share compared to $0.76 per share in Q2 2023. Q2 2024 Entered Orders decreased...

FARGO, N.D., May 09, 2024 (GLOBE NEWSWIRE) — NI Holdings, Inc. (NASDAQ: NODK) announced today results for the quarter ended March 31, 2024. Summary of First Quarter 2024 Results(All comparisons vs. the first quarter of 2023, unless noted otherwise)Direct written premiums of $102.7 million, up 13.4%, driven by increases in Non-Standard Auto (23.2%), Home and Farm (13.1%) and Private Passenger Auto (7.9%). Net earned premiums of $85.6 million, up 10.2%. Combined ratio of 97.2% versus 112.2%, driven by the earned impact of prior period rate increases across all segments (excluding Crop) and lower weather-related losses in Private Passenger Auto and Commercial, partially offset by unfavorable development in Non-Standard Auto. Net investment gain of $1.8 million and net investment income of $3.6 million, driven by improved equity...